A quick cure for Alzheimer’s?

Related posts:

1. FDA delays decision on donanemab The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein that demonstrated efficacy in early Alzheimer’s disease in a recent Phase 3 clinical trial. A positive decision to approve donanemab...
2. FDA Advisory Panel meeting held to consider potential approval of donanemab Today, the FDA convened its Peripheral and Central Nervous System Drugs Advisory Committee to review the data from pivotal clinical trials of donanemab, a monoclonal antibody against the beta amyloid protein that accumulates in the brain of people with Alzheimer’s disease. One of these trials was conducted at UCI MIND....
3. AlzForum provides update on MODEL-AD at UCI AlzForum, the popular online publication for Alzheimer’s researchers, published a summary of recent advances from the MODEL-AD teams and highlighted the work of the principal investigators at UCI, Drs. Kim Green, Andrea Tenner, and Frank LaFerla.  The article also called attention to innovative research in the Green Lab, including work...